Travere Therapeutics (TVTX) Financials

$44.80 -0.11 (-0.24%)

Closing price 04:00 PM Eastern

Extended Trading

$44.00 -0.80 (-1.79%)

As of 04:38 PM Eastern

Annual Income Statements for Travere Therapeutics

This table shows Travere Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	117	-48	-60	-103	-146	-169	-180	-278	-111	-322	-26
Consolidated Net Income / (Loss)	117	-48	-60	-103	-146	-169	-180	-278	-111	-322	-26
Net Income / (Loss) Continuing Operations	117	-48	-60	-103	-146	-169	-217	-331	-376	-321	-50
Total Pre-Tax Income	105	-58	-58	-102	-146	-189	-217	-331	-376	-321	-49
Total Operating Income	-51	-58	-54	-80	-137	-176	-199	-320	-388	-324	-63
Total Gross Profit	98	129	151	159	170	192	128	105	134	225	480
Total Revenue	100	134	155	164	175	198	132	109	145	233	491
Operating Revenue	100	134	155	164	175	198	132	109	145	233	491
Total Cost of Revenue	2.19	4.55	3.61	5.53	5.23	6.13	3.82	4.42	11	7.74	10
Operating Cost of Revenue	2.19	4.55	3.61	5.53	5.23	6.13	3.82	4.42	11	7.74	10
Total Operating Expenses	148	187	205	239	307	368	327	425	522	549	543
Selling, General & Admin Expense	80	92	101	104	129	136	126	198	266	264	337
Research & Development Expense	50	71	78	124	141	229	201	227	245	283	206
Restructuring Charge	0.00	0.89	3.61	-0.24	-	-	0.00	0.00	11	2.44	0.00
Total Other Income / (Expense), net	156	0.67	-4.57	-22	-9.09	-13	-17	-11	12	3.32	14
Interest Expense	4.15	0.73	4.42	27	-	0.00	0.00	19	11	11	11
Interest & Investment Income	-7.75	-	3.23	5.50	-8.77	-14	-18	6.28	22	18	13
Other Income / (Expense), net	168	1.39	-3.38	-0.47	-0.31	1.42	0.23	0.97	1.59	-3.32	12
Income Tax Expense	-12	-9.68	1.37	0.81	-0.02	-19	0.41	0.31	0.22	0.12	0.99
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-	37	53	265	-0.92	25
Basic Earnings per Share	$3.49	($1.29)	($1.54)	($2.54)	($3.46)	($3.56)	($3.01)	($4.37)	($1.50)	($4.08)	($0.29)
Weighted Average Basic Shares Outstanding	33.56M	37.00M	38.77M	40.43M	42.34M	47.54M	59.83M	63.76M	74.27M	78.89M	89.21M
Diluted Earnings per Share	$3.17	($1.29)	($1.54)	($2.54)	($3.46)	($3.56)	($3.01)	($4.37)	($1.50)	($4.08)	($0.29)
Weighted Average Diluted Shares Outstanding	37.58M	38.29M	38.77M	40.43M	42.34M	47.54M	59.83M	63.76M	74.27M	78.89M	89.21M
Weighted Average Basic & Diluted Shares Outstanding	33.60M	37.10M	38.77M	40.43M	42.34M	47.54M	63.21M	64.74M	76.10M	88.74M	92.24M

This table shows Travere Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-86	151	-90	-136	-70	-55	-61	-41	-13	26	2.73
Consolidated Net Income / (Loss)	-86	151	-90	-136	-70	-55	-60	-41	-13	26	2.73
Net Income / (Loss) Continuing Operations	-102	-89	-89	-136	-70	-55	-60	-41	-13	26	-22
Total Pre-Tax Income	-102	-89	-89	-136	-70	-55	-60	-41	-13	26	-21
Total Operating Income	-104	-93	-94	-139	-68	-56	-61	-43	-13	25	-32
Total Gross Profit	31	36	40	40	52	61	72	77	113	163	127
Total Revenue	32	37	45	41	54	63	75	82	114	165	130
Operating Revenue	32	37	45	41	54	63	75	82	114	165	130
Total Cost of Revenue	1.45	1.29	4.56	1.50	2.06	1.63	2.55	4.68	1.52	1.59	2.55
Operating Cost of Revenue	1.45	1.29	4.56	1.50	2.06	1.63	2.55	4.68	1.52	1.59	2.55
Total Operating Expenses	135	128	135	179	120	117	133	120	126	138	160
Selling, General & Admin Expense	68	68	64	64	65	66	70	73	76	86	102
Research & Development Expense	66	61	60	115	54	52	62	47	49	52	58
Total Other Income / (Expense), net	2.08	3.36	5.71	3.47	-1.86	1.31	0.40	1.49	-0.09	0.78	11
Interest Expense	2.84	2.82	-	2.80	2.79	2.78	-	2.86	2.85	2.75	2.29
Interest & Investment Income	5.13	5.84	10	6.03	4.42	3.57	6.60	3.80	3.29	3.05	2.59
Other Income / (Expense), net	-0.20	0.34	1.37	0.24	-3.50	0.52	-0.58	0.55	-0.53	0.49	11
Income Tax Expense	0.07	0.01	0.07	0.19	0.09	-0.08	-0.07	0.04	0.02	0.01	0.92
Net Income / (Loss) Discontinued Operations	16	240	-1.58	-0.10	-0.76	-0.06	0.00	0.00	0.00	0.00	25
Basic Earnings per Share	($1.13)	$1.97	($1.07)	($1.76)	($0.91)	($0.70)	($0.71)	($0.47)	($0.14)	$0.29	$0.03
Weighted Average Basic Shares Outstanding	76.00M	76.31M	74.27M	77.14M	77.50M	77.78M	78.89M	88.36M	88.95M	89.23M	89.21M
Diluted Earnings per Share	($1.13)	$1.97	($1.07)	($1.76)	($0.91)	($0.70)	($0.71)	($0.47)	($0.14)	$0.28	$0.04
Weighted Average Diluted Shares Outstanding	76.00M	76.31M	74.27M	77.14M	77.50M	77.78M	78.89M	88.36M	88.95M	102.62M	89.21M
Weighted Average Basic & Diluted Shares Outstanding	75.01M	75.15M	76.10M	76.13M	76.49M	78.05M	88.74M	88.80M	89.14M	89.47M	92.24M

This table details how cash moves in and out of Travere Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	20	3.20	58	3.48	-40	22	81	-104	-3.51	1.27	35
Net Cash From Operating Activities	-1.39	-3.44	7.40	-25	-58	-43	-15	-186	-280	-237	38
Net Cash From Continuing Operating Activities	-1.39	-3.44	7.40	-25	-58	-43	-76	-261	-325	-230	38
Net Income / (Loss) Continuing Operations	117	-48	-60	-103	-146	-169	-217	-331	-376	-321	-50
Consolidated Net Income / (Loss)	117	-48	-60	-103	-146	-169	-180	-278	-111	-322	-26
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-	37	53	265	-0.92	25
Depreciation Expense	13	16	18	19	20	25	13	21	39	44	61
Amortization Expense	1.74	1.75	1.99	3.78	9.12	10	13	0.92	-5.74	-2.81	-2.80
Non-Cash Adjustments To Reconcile Net Income	-121	26	31	53	62	130	34	48	44	113	44
Changes in Operating Assets and Liabilities, net	-13	0.93	17	2.53	-3.04	-38	81	0.88	-25	-63	-14
Net Cash From Discontinued Operating Activities	-	-	-	-	-	-	61	75	45	-7.45	0.00
Net Cash From Investing Activities	-81	10	46	-203	20	-61	-138	-33	56	99	28
Net Cash From Continuing Investing Activities	-81	10	46	-203	20	-61	-138	-33	-152	99	28
Acquisitions	-40	-11	-13	-34	-15	-113	-19	-28	-42	-36	-58
Purchase of Investments	-199	-184	-102	-331	-224	-215	-547	-385	-444	-126	-237
Sale and/or Maturity of Investments	9.98	207	162	163	259	273	434	382	335	326	324
Other Investing Activities, net	0.00	0.00	-	-	-	0.00	0.00	-0.79	-0.67	-65	-0.40
Net Cash From Discontinued Investing Activities	-	-	-	-	-	-	0.00	0.00	207	0.00	0.00
Net Cash From Financing Activities	102	-3.85	5.45	232	-2.08	128	232	118	219	139	-33
Net Cash From Continuing Financing Activities	102	-3.85	5.45	232	-2.08	128	238	120	220	139	-33
Repayment of Debt	-47	-1.36	-0.85	-41	-	0.00	0.00	-221	0.00	0.00	-69
Issuance of Common Equity	154	6.01	3.65	5.31	1.78	134	227	23	219	137	2.79
Other Financing Activities, net	4.14	-8.50	1.99	-1.13	-3.85	-5.85	11	2.49	1.14	2.35	33
Net Cash From Discontinued Financing Activities	-	-	-	-	-	-	-6.10	-2.48	-1.38	0.00	0.00
Other Net Changes in Cash	-	-	-	-	-	-	-	-	1.98	-	2.29
Cash Interest Paid	5.84	2.07	2.07	1.88	7.67	6.90	7.33	10	8.84	8.84	8.84

This table details how cash moves in and out of Travere Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Change in Cash & Equivalents	-91	73	-86	-15	-11	4.12	23	3.36	13	36	-18
Net Cash From Operating Activities	-69	-59	-70	-119	-40	-43	-36	-42	4.98	14	61
Net Cash From Continuing Operating Activities	-88	-74	-64	-119	-40	-43	-29	-42	4.98	14	61
Net Income / (Loss) Continuing Operations	-102	-89	-89	-136	-70	-55	-60	-41	-13	26	-22
Consolidated Net Income / (Loss)	-86	151	-90	-136	-70	-55	-60	-41	-13	26	2.73
Net Income / (Loss) Discontinued Operations	16	240	-1.58	-0.10	-0.76	-0.06	0.00	0.00	-	-	25
Depreciation Expense	11	11	9.49	9.88	10	11	12	13	14	16	18
Non-Cash Adjustments To Reconcile Net Income	9.68	8.23	13	10	80	7.69	15	9.92	9.36	10	15
Changes in Operating Assets and Liabilities, net	-6.60	-4.90	8.09	-2.95	-61	-6.74	7.40	-24	-5.64	-37	53
Net Cash From Investing Activities	-24	133	-17	105	29	46	-80	41	4.85	87	-105
Net Cash From Continuing Investing Activities	-24	-73	-18	105	29	46	-80	41	4.85	87	-105
Acquisitions	-3.83	-4.92	-5.51	-6.47	-12	-8.19	-9.64	-12	-12	-15	-19
Purchase of Investments	-122	-156	-63	-	-	-	-126	-	-	-4.85	-168
Sale and/or Maturity of Investments	103	88	50	111	106	54	55	53	81	107	82
Other Investing Activities, net	-	-	-	0.00	-	-	-0.04	-0.08	0.15	0.00	-0.47
Net Cash From Financing Activities	2.27	-0.63	0.12	-0.53	0.78	0.05	139	3.72	1.48	-65	27
Net Cash From Continuing Financing Activities	2.53	-0.37	0.38	-0.53	0.78	0.05	139	3.72	1.48	-65	27
Issuance of Common Equity	2.26	-	0.91	-	1.31	-	136	-	-	-	1.26
Other Financing Activities, net	0.27	-0.37	1.58	-0.53	-0.53	0.05	3.36	3.72	-0.06	3.57	25
Other Net Changes in Cash	0.08	-0.18	-	-0.29	-	-	-	0.55	1.95	0.21	-0.41

This table presents Travere Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	512	525	520	709	605	607	777	673	789	594	605
Total Current Assets	302	332	326	496	429	410	583	486	617	417	438
Cash & Equivalents	38	41	99	103	62	85	166	62	58	59	93
Short-Term Investments	192	215	201	369	336	277	387	389	509	312	230
Accounts Receivable	12	19	14	13	18	16	16	17	21	27	80
Inventories, net	2.54	2.83	5.35	5.62	6.08	7.61	7.31	4.52	9.41	6.20	5.88
Prepaid Expenses	2.38	4.83	3.11	4.14	5.02	8.14	6.72	12	19	13	29
Plant, Property, & Equipment, net	0.43	2.59	3.23	3.15	2.89	9.42	11	9.05	7.48	5.34	4.02
Total Noncurrent Assets	210	190	191	210	173	188	183	177	165	172	164
Intangible Assets	162	182	185	187	157	154	148	97	104	104	114
Other Noncurrent Operating Assets	1.86	7.36	5.56	7.71	15	33	34	32	60	68	50
Total Liabilities & Shareholders' Equity	512	525	520	709	605	607	777	673	789	594	605
Total Liabilities	212	218	227	391	384	396	475	630	588	535	490
Total Current Liabilities	87	83	86	105	95	93	124	142	178	201	160
Short-Term Debt	-	-	0.00	22	-	17	7.40	-	0.00	69	0.00
Accounts Payable	7.64	7.52	19	6.95	27	12	15	17	42	24	25
Accrued Expenses	26	35	38	50	52	57	75	96	119	86	126
Other Current Liabilities	54	40	29	26	17	6.33	10	10	10	23	9.07
Total Noncurrent Liabilities	125	134	142	286	288	304	350	488	410	334	330
Long-Term Debt	44	44	45	195	205	215	227	376	377	310	312
Other Noncurrent Operating Liabilities	57	83	96	91	83	88	103	37	33	24	19
Commitments & Contingencies	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	300	308	293	318	221	211	302	43	201	59	115
Total Preferred & Common Equity	300	308	293	318	221	211	302	43	201	59	115
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	300	308	293	318	221	211	302	43	201	59	115
Common Stock	366	421	472	590	637	798	1,069	1,060	1,328	1,506	1,589
Retained Earnings	-65	-113	-178	-270	-416	-586	-766	-1,014	-1,126	-1,447	-1,473
Accumulated Other Comprehensive Income / (Loss)	-0.68	-0.49	-1.02	-1.53	0.73	-0.90	-0.56	-2.91	-1.46	-0.08	-1.19

This table presents Travere Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025
Total Assets	726	808	736	833	664	551	504	549	555	539
Total Current Assets	535	605	542	686	481	369	325	374	380	371
Cash & Equivalents	151	161	71	144	43	32	36	62	75	111
Short-Term Investments	355	400	420	490	398	293	241	260	244	144
Accounts Receivable	13	22	20	15	23	24	25	34	39	83
Inventories, net	7.30	6.71	19	21	4.53	5.98	6.36	3.93	4.09	5.55
Prepaid Expenses	8.55	15	12	16	13	13	16	14	17	28
Plant, Property, & Equipment, net	9.56	9.13	8.57	8.00	6.94	6.58	6.16	4.85	4.56	4.32
Total Noncurrent Assets	182	194	186	139	176	176	174	170	171	163
Intangible Assets	149	163	154	107	101	105	104	104	106	109
Other Noncurrent Operating Assets	32	31	31	32	74	70	69	66	66	54
Total Liabilities & Shareholders' Equity	726	808	736	833	664	551	504	549	555	539
Total Liabilities	626	619	620	553	589	536	535	516	523	465
Total Current Liabilities	131	131	136	139	173	121	190	182	190	135
Short-Term Debt	7.30	6.90	6.90	-	-	-	69	69	69	0.00
Accounts Payable	14	17	20	25	17	26	23	15	19	18
Accrued Expenses	88	86	89	96	140	80	84	77	82	106
Other Current Liabilities	9.96	10	9.90	10	10	10	11	21	20	11
Total Noncurrent Liabilities	495	488	484	414	416	415	345	334	333	330
Long-Term Debt	375	376	376	377	378	378	310	311	311	311
Other Noncurrent Operating Liabilities	106	104	101	32	38	37	35	23	22	19
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	101	189	116	280	74	15	-30	33	33	74
Total Preferred & Common Equity	101	189	116	280	74	15	-30	33	33	74
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	101	189	116	280	74	15	-30	33	33	74
Common Stock	1,049	1,292	1,307	1,319	1,338	1,349	1,357	1,522	1,535	1,550
Retained Earnings	-948	-1,101	-1,186	-1,035	-1,262	-1,332	-1,387	-1,488	-1,501	-1,475
Accumulated Other Comprehensive Income / (Loss)	0.30	-2.18	-3.86	-3.65	-1.89	-1.63	-1.02	-0.84	-0.81	-1.05

This table displays calculated financial ratios and metrics derived from Travere Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	254.19%	33.74%	15.98%	6.01%	6.75%	13.11%	-33.52%	-16.97%	32.69%	60.55%	110.45%
EBITDA Growth	239.81%	-129.39%	4.00%	-55.35%	-86.26%	-29.16%	-23.99%	-71.59%	-19.03%	19.04%	102.34%
EBIT Growth	210.76%	-148.42%	-0.62%	-40.82%	-71.00%	-26.92%	-13.99%	-60.06%	-21.23%	15.37%	84.34%
NOPAT Growth	-0.98%	27.76%	7.60%	-48.80%	-71.62%	-28.25%	-13.20%	-60.37%	-21.36%	16.57%	80.60%
Net Income Growth	205.68%	-140.86%	-24.69%	-71.90%	-42.61%	-15.71%	-6.29%	-54.63%	60.00%	-188.64%	92.06%
EPS Growth	171.56%	-140.69%	-19.38%	-64.94%	-36.22%	-2.89%	15.45%	-45.18%	65.68%	-172.00%	92.89%
Operating Cash Flow Growth	96.97%	-147.73%	315.14%	-437.13%	-133.25%	26.58%	65.39%	-1,159.40%	-50.31%	15.19%	115.91%
Free Cash Flow Firm Growth	-51.08%	84.89%	191.93%	-421.17%	-9.92%	-139.36%	77.30%	-465.40%	-28.96%	4.10%	71.58%
Invested Capital Growth	508.29%	-15.61%	-60.98%	31.08%	-44.11%	199.14%	-120.38%	28.64%	193.67%	500.29%	54.02%
Revenue Q/Q Growth	19.59%	5.43%	3.23%	0.98%	1.69%	38.80%	-51.60%	18.56%	84.06%	14.61%	12.60%
EBITDA Q/Q Growth	7.24%	6.77%	4.77%	11.46%	-25.34%	-176.17%	11.18%	-3.67%	2.57%	9.86%	118.36%
EBIT Q/Q Growth	10.85%	4.65%	2.44%	6.52%	-19.77%	-106.47%	14.41%	-6.82%	2.99%	8.79%	43.81%
NOPAT Q/Q Growth	-2.62%	-5.47%	5.36%	11.30%	-20.30%	-28.66%	-9.58%	-6.95%	2.85%	9.37%	31.06%
Net Income Q/Q Growth	29.29%	-14.69%	-17.78%	9.01%	-18.45%	-117.03%	28.00%	-5.39%	-27.97%	8.51%	71.15%
EPS Q/Q Growth	13.21%	-98.46%	-60.42%	8.63%	-17.69%	-109.41%	36.63%	-5.05%	-2.74%	8.11%	72.12%
Operating Cash Flow Q/Q Growth	79.96%	-329.40%	3,236.86%	-12.19%	-1.62%	-28.11%	-728.68%	-17.51%	-5.99%	12.77%	164.46%
Free Cash Flow Firm Q/Q Growth	-26.93%	-37.29%	370.47%	-16.76%	7.95%	-58.59%	18.25%	-10.90%	9.22%	5.36%	34.94%
Invested Capital Q/Q Growth	14.73%	24.20%	-17.51%	21.99%	-33.35%	42.50%	16.55%	48.43%	-48.89%	-4.67%	-20.44%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	97.81%	96.59%	97.67%	96.63%	97.01%	96.91%	97.10%	95.96%	92.12%	96.68%	97.89%
EBITDA Margin	132.64%	-29.14%	-24.12%	-35.35%	-61.68%	-70.43%	-131.37%	-271.51%	-243.57%	-122.83%	1.37%
Operating Margin	-50.80%	-43.58%	-34.72%	-48.73%	-78.34%	-88.83%	-151.27%	-292.17%	-267.24%	-138.88%	-12.80%
EBIT Margin	117.49%	-42.54%	-36.90%	-49.02%	-78.52%	-88.11%	-151.09%	-291.28%	-266.15%	-140.30%	-10.44%
Profit (Net Income) Margin	117.36%	-35.86%	-38.55%	-62.51%	-83.51%	-85.43%	-136.60%	-254.41%	-76.70%	-137.90%	-5.21%
Tax Burden Percent	111.16%	83.19%	102.34%	100.80%	99.99%	89.75%	83.04%	84.09%	29.62%	100.32%	51.85%
Interest Burden Percent	89.86%	101.34%	102.08%	126.52%	106.37%	108.04%	108.88%	103.86%	97.30%	97.97%	96.15%
Effective Tax Rate	-11.16%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-84.90%	-38.73%	-56.24%	-129.04%	-250.42%	-224.42%	-425.77%	0.00%	0.00%	-576.89%	-51.40%
ROIC Less NNEP Spread (ROIC-NNEP)	-352.41%	-35.13%	-46.79%	-111.25%	-228.69%	-195.82%	-407.68%	0.00%	0.00%	-472.24%	-1,374.98%
Return on Net Nonoperating Assets (RNNOA)	174.14%	22.96%	36.36%	95.45%	196.13%	146.05%	355.60%	0.00%	0.00%	329.44%	22.02%
Return on Equity (ROE)	89.25%	-15.76%	-19.88%	-33.59%	-54.29%	-78.37%	-70.17%	-161.46%	-91.44%	-247.45%	-29.38%
Cash Return on Invested Capital (CROIC)	-228.42%	-21.79%	31.49%	-155.93%	-193.83%	-324.20%	0.00%	0.00%	-2,627.87%	-719.77%	-93.93%
Operating Return on Assets (OROA)	36.24%	-10.95%	-10.94%	-13.10%	-20.96%	-28.83%	-28.78%	-44.00%	-52.90%	-47.31%	-8.55%
Return on Assets (ROA)	36.20%	-9.23%	-11.42%	-16.70%	-22.29%	-27.95%	-26.02%	-38.43%	-15.24%	-46.50%	-4.26%
Return on Common Equity (ROCE)	89.25%	-15.76%	-19.88%	-33.59%	-54.29%	-78.37%	-70.17%	-161.46%	-91.44%	-247.45%	-29.38%
Return on Equity Simple (ROE_SIMPLE)	39.08%	-15.56%	-20.38%	-32.26%	-66.20%	-80.22%	-59.61%	-649.88%	-55.47%	-544.28%	0.00%
Net Operating Profit after Tax (NOPAT)	-56	-41	-38	-56	-96	-123	-140	-224	-272	-227	-44
NOPAT Margin	-56.47%	-30.50%	-24.30%	-34.11%	-54.84%	-62.18%	-105.89%	-204.52%	-187.07%	-97.21%	-8.96%
Net Nonoperating Expense Percent (NNEP)	267.51%	-3.60%	-9.45%	-17.79%	-21.73%	-28.60%	-18.09%	-29.23%	131.17%	-104.65%	1,323.58%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-53.51%	-47.00%	-51.75%	-10.31%
Cost of Revenue to Revenue	2.19%	3.41%	2.33%	3.37%	2.99%	3.09%	2.90%	4.04%	7.88%	3.32%	2.11%
SG&A Expenses to Revenue	79.63%	68.82%	65.40%	63.11%	73.54%	68.47%	95.79%	180.45%	182.83%	113.27%	68.71%
R&D to Revenue	50.48%	53.01%	50.45%	75.35%	80.40%	115.42%	152.58%	207.69%	168.68%	121.24%	41.98%
Operating Expenses to Revenue	148.62%	140.17%	132.39%	145.37%	175.36%	185.74%	248.37%	388.14%	359.36%	235.56%	110.70%
Earnings before Interest and Taxes (EBIT)	117	-57	-57	-81	-138	-175	-199	-319	-387	-327	-51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	132	-39	-37	-58	-108	-140	-173	-297	-354	-286	6.70
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.32	2.32	2.83	2.93	2.76	6.59	6.29	31.49	3.36	23.01	29.77
Price to Tangible Book Value (P/TBV)	5.07	5.72	7.71	7.15	9.67	24.37	12.37	0.00	7.01	0.00	3,561.19
Price to Revenue (P/Rev)	6.98	5.35	5.35	5.68	3.48	7.02	14.42	12.33	4.65	5.83	6.97
Price to Earnings (P/E)	5.95	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	16.81%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.48	5.22	15.24	13.49	15.12	15.33	0.00	0.00	43.31	20.31	32.84
Enterprise Value to Revenue (EV/Rev)	5.12	3.76	3.70	4.05	2.37	6.37	12.00	11.65	3.35	5.87	6.94
Enterprise Value to EBITDA (EV/EBITDA)	3.86	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	508.53
Enterprise Value to EBIT (EV/EBIT)	4.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	77.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	90.19
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	27.16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.15	0.14	0.15	0.68	0.93	1.10	0.77	8.76	1.88	6.42	2.71
Long-Term Debt to Equity	0.15	0.14	0.15	0.61	0.93	1.02	0.75	8.76	1.88	5.25	2.71
Financial Leverage	-0.49	-0.65	-0.78	-0.86	-0.86	-0.75	-0.87	-1.08	-1.00	-0.70	-0.02
Leverage Ratio	2.47	1.71	1.74	2.01	2.44	2.80	2.70	4.20	6.00	5.32	6.90
Compound Leverage Factor	2.22	1.73	1.78	2.54	2.59	3.03	2.94	4.36	5.84	5.21	6.63
Debt to Total Capital	12.73%	12.61%	13.33%	40.60%	48.08%	52.42%	43.65%	89.76%	65.26%	86.51%	73.08%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	4.19%	0.00%	3.92%	1.38%	0.00%	0.00%	15.68%	0.00%
Long-Term Debt to Total Capital	12.73%	12.61%	13.33%	36.41%	48.08%	48.51%	42.27%	89.76%	65.26%	70.84%	73.08%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	87.27%	87.39%	86.67%	59.40%	51.92%	47.58%	56.35%	10.24%	34.74%	13.49%	26.92%
Debt to EBITDA	0.33	-1.14	-1.21	-3.75	-1.89	-1.67	-1.35	-1.26	-1.07	-1.32	46.52
Net Debt to EBITDA	-1.40	5.43	6.84	4.63	1.79	0.92	1.84	0.25	0.54	-0.03	-1.65
Long-Term Debt to EBITDA	0.33	-1.14	-1.21	-3.36	-1.89	-1.54	-1.31	-1.26	-1.07	-1.08	46.52
Debt to NOPAT	-0.78	-1.09	-1.20	-3.88	-2.13	-1.89	-1.68	-1.68	-1.39	-1.67	-7.09
Net Debt to NOPAT	3.29	5.19	6.79	4.80	2.01	1.04	2.28	0.33	0.70	-0.04	0.25
Long-Term Debt to NOPAT	-0.78	-1.09	-1.20	-3.48	-2.13	-1.75	-1.62	-1.68	-1.39	-1.37	-7.09
Altman Z-Score	3.25	2.14	2.20	1.42	0.19	0.76	1.05	-1.61	-2.07	-2.87	1.86
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.47	3.99	3.80	4.74	4.50	4.43	4.70	3.42	3.47	2.08	2.74
Quick Ratio	3.32	3.86	3.67	4.63	4.36	4.07	4.58	3.28	3.31	1.98	2.52
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-152	-23	21	-68	-74	-178	-40	-229	-295	-283	-80
Operating Cash Flow to CapEx	0.00%	-240.97%	834.61%	-3,433.01%	-29,853.33%	-631.64%	-289.98%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-36.57	-31.63	4.77	-2.52	0.00	0.00	0.00	-12.30	-26.02	-25.29	-7.48
Operating Cash Flow to Interest Expense	-0.33	-4.75	1.67	-0.93	0.00	0.00	0.00	-10.02	-24.71	-21.24	3.52
Operating Cash Flow Less CapEx to Interest Expense	35.41	-6.72	1.47	-0.96	0.00	0.00	0.00	-10.02	-24.71	-21.24	3.52
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.31	0.26	0.30	0.27	0.27	0.33	0.19	0.15	0.20	0.34	0.82
Accounts Receivable Turnover	9.78	8.63	9.57	12.38	11.42	11.68	8.28	6.72	7.68	9.66	9.15
Inventory Turnover	1.31	1.70	0.88	1.01	0.89	0.90	0.51	0.75	1.64	0.99	1.71
Fixed Asset Turnover	181.79	88.62	53.27	51.52	58.09	32.22	12.85	10.86	17.57	36.39	104.88
Accounts Payable Turnover	0.30	0.60	0.27	0.43	0.31	0.32	0.28	0.27	0.39	0.24	0.43
Days Sales Outstanding (DSO)	37.30	42.31	38.14	29.48	31.96	31.26	44.07	54.29	47.53	37.80	39.89
Days Inventory Outstanding (DIO)	278.72	214.88	413.95	362.23	407.99	407.84	713.22	488.70	222.08	367.88	213.14
Days Payable Outstanding (DPO)	1,233.07	607.57	1,339.51	854.95	1,170.45	1,154.31	1,303.84	1,339.19	939.84	1,536.76	853.17
Cash Conversion Cycle (CCC)	-917.04	-350.39	-887.42	-463.24	-730.50	-715.21	-546.54	-796.20	-670.23	-1,131.08	-600.14
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	114	96	38	49	28	82	-17	-12	11	67	104
Invested Capital Turnover	1.50	1.27	2.31	3.78	4.57	3.61	4.02	-7.61	-382.71	5.93	5.74
Increase / (Decrease) in Invested Capital	95	-18	-59	12	-22	55	-99	4.81	23	56	36
Enterprise Value (EV)	511	503	573	664	416	1,263	1,582	1,275	486	1,368	3,408
Market Capitalization	697	714	828	933	610	1,391	1,900	1,350	676	1,360	3,419
Book Value per Share	$8.30	$8.16	$7.46	$7.72	$5.15	$4.14	$4.93	$0.67	$2.67	$0.76	$1.28
Tangible Book Value per Share	$3.80	$3.31	$2.73	$3.17	$1.47	$1.12	$2.51	($0.84)	$1.28	($0.58)	$0.01
Total Capital	344	352	338	536	426	444	536	418	578	438	427
Total Debt	44	44	45	218	205	233	234	376	377	379	312
Total Long-Term Debt	44	44	45	195	205	215	227	376	377	310	312
Net Debt	-186	-211	-256	-269	-194	-129	-319	-75	-190	8.29	-11
Capital Expenditures (CapEx)	-148	1.43	0.89	0.73	0.20	6.77	5.10	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-15	-6.78	-60	-58	-65	-26	-87	-106	-128	-86	-45
Debt-free Net Working Capital (DFNWC)	215	249	240	414	334	335	466	344	439	285	278
Net Working Capital (NWC)	215	249	240	391	334	318	459	344	439	216	278
Net Nonoperating Expense (NNE)	-174	7.15	22	47	50	46	40	55	-160	95	-18
Net Nonoperating Obligations (NNO)	-186	-211	-256	-269	-194	-129	-319	-55	-190	8.29	-11
Total Depreciation and Amortization (D&A)	15	18	20	22	30	35	26	22	33	41	58
Debt-free, Cash-free Net Working Capital to Revenue	-14.67%	-5.08%	-39.04%	-35.33%	-37.02%	-13.33%	-65.80%	-96.81%	-88.12%	-36.91%	-9.20%
Debt-free Net Working Capital to Revenue	215.18%	186.46%	154.99%	251.77%	190.27%	168.99%	353.57%	314.52%	302.17%	122.07%	56.58%
Net Working Capital to Revenue	215.18%	186.46%	154.99%	238.09%	190.27%	160.22%	347.96%	314.52%	302.17%	92.61%	56.58%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.49	($1.29)	($1.54)	($2.54)	($3.46)	($3.56)	($3.01)	($4.37)	($1.50)	($4.08)	($0.29)
Adjusted Weighted Average Basic Shares Outstanding	33.56M	37.00M	38.77M	40.43M	43.12M	60.24M	59.83M	63.76M	74.27M	78.89M	89.21M
Adjusted Diluted Earnings per Share	$3.17	($1.29)	($1.54)	($2.54)	($3.46)	($3.56)	($3.01)	($4.37)	($1.50)	($4.08)	($0.29)
Adjusted Weighted Average Diluted Shares Outstanding	37.58M	38.29M	38.77M	40.43M	43.12M	60.24M	59.83M	63.76M	74.27M	78.89M	89.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($2.54)	($3.46)	($3.56)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	36.51M	38.09M	39.69M	41.41M	42.34M	47.54M	63.21M	64.74M	76.10M	88.74M	92.24M
Normalized Net Operating Profit after Tax (NOPAT)	-23	-24	-33	-56	-68	-123	-140	-224	-264	-225	-44
Normalized NOPAT Margin	-22.61%	-17.67%	-21.49%	-34.22%	-38.67%	-62.18%	-105.89%	-204.52%	-181.58%	-96.48%	-8.96%
Pre Tax Income Margin	105.58%	-43.10%	-37.67%	-62.02%	-83.52%	-95.19%	-164.51%	-302.54%	-258.96%	-137.45%	-10.04%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	28.27	-78.38	-12.93	-3.00	0.00	0.00	0.00	-17.15	-34.10	-29.26	-4.77
NOPAT to Interest Expense	-13.59	-56.21	-8.52	-2.09	0.00	0.00	0.00	-12.04	-23.97	-20.27	-4.09
EBIT Less CapEx to Interest Expense	64.02	-80.35	-13.13	-3.03	0.00	0.00	0.00	-17.15	-34.10	-29.26	-4.77
NOPAT Less CapEx to Interest Expense	22.16	-58.18	-8.72	-2.11	0.00	0.00	0.00	-12.04	-23.97	-20.27	-4.09
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	8.10%	0.00%	0.00%	-8.59%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Travere Therapeutics' official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-40.56%	32.13%	311.85%	33.95%	68.08%	69.56%	65.98%	97.54%	111.49%	162.11%	73.41%
EBITDA Growth	-64.44%	4.47%	14.79%	-42.42%	34.71%	45.04%	40.96%	77.29%	101.38%	192.83%	93.45%
EBIT Growth	-60.76%	-10.89%	11.36%	-42.88%	31.64%	39.70%	33.97%	69.69%	81.49%	145.69%	65.16%
NOPAT Growth	-58.82%	-12.08%	10.79%	-43.00%	34.87%	39.35%	35.55%	69.35%	81.32%	163.41%	46.60%
Net Income Growth	-27.75%	316.40%	-36.99%	-57.60%	17.78%	-136.36%	33.17%	69.70%	81.88%	146.90%	104.53%
EPS Growth	-7.62%	280.73%	-3.88%	-38.58%	19.47%	-135.53%	33.64%	73.30%	84.62%	140.00%	105.63%
Operating Cash Flow Growth	-88.28%	-49.61%	-28.98%	-46.71%	41.93%	28.12%	49.31%	64.54%	112.38%	133.68%	269.87%
Free Cash Flow Firm Growth	-9,747.35%	-101.07%	-13.23%	-6.09%	-11.63%	19.99%	-10.65%	-11.74%	68.13%	60.44%	40.10%
Invested Capital Growth	158.40%	194.50%	193.67%	2.09%	703.17%	221.84%	500.29%	739.57%	37.11%	84.54%	54.02%
Revenue Q/Q Growth	4.23%	15.22%	21.47%	-8.18%	30.80%	16.23%	18.90%	9.29%	40.03%	44.05%	-21.33%
EBITDA Q/Q Growth	-2.80%	13.34%	-3.22%	-53.84%	52.87%	27.05%	-10.90%	40.43%	102.86%	4,805.48%	-107.83%
EBIT Q/Q Growth	-7.06%	11.43%	-0.66%	-49.69%	48.78%	21.87%	-10.23%	31.30%	68.72%	292.91%	-184.05%
NOPAT Q/Q Growth	-6.76%	10.93%	-1.78%	-47.76%	51.38%	17.07%	-8.17%	29.74%	70.36%	381.46%	-191.09%
Net Income Q/Q Growth	0.81%	276.03%	-159.82%	-50.89%	48.25%	22.15%	-9.95%	31.59%	69.06%	301.54%	-89.38%
EPS Q/Q Growth	11.02%	274.34%	-154.31%	-64.49%	48.30%	23.08%	-1.43%	33.80%	70.21%	300.00%	-85.71%
Operating Cash Flow Q/Q Growth	14.57%	14.67%	-19.18%	-68.87%	66.18%	-5.63%	15.97%	-18.12%	111.81%	187.32%	323.82%
Free Cash Flow Firm Q/Q Growth	-3.92%	-14.96%	18.94%	-9.55%	-9.35%	17.61%	-12.10%	-10.64%	68.81%	-2.28%	-69.72%
Invested Capital Q/Q Growth	-19.52%	159.80%	-48.89%	-4.47%	533.17%	4.11%	-4.67%	33.61%	3.40%	40.12%	-20.44%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	95.49%	96.53%	89.87%	96.36%	96.19%	97.41%	96.59%	94.28%	98.67%	99.04%	98.03%
EBITDA Margin	-289.49%	-217.75%	-185.03%	-312.08%	-112.45%	-70.57%	-65.82%	-35.88%	0.73%	24.99%	-2.49%
Operating Margin	-322.87%	-249.59%	-209.13%	-336.53%	-125.11%	-89.27%	-81.21%	-52.21%	-11.05%	15.12%	-25.01%
EBIT Margin	-323.49%	-248.69%	-206.09%	-335.96%	-131.57%	-88.44%	-81.99%	-51.54%	-11.51%	15.42%	-16.47%
Profit (Net Income) Margin	-265.96%	406.35%	-200.12%	-328.86%	-130.11%	-87.14%	-80.58%	-50.44%	-11.14%	15.59%	2.10%
Tax Burden Percent	84.06%	-168.93%	101.86%	100.22%	101.21%	99.95%	99.87%	100.09%	100.16%	99.97%	-12.96%
Interest Burden Percent	97.81%	96.73%	95.33%	97.67%	97.71%	98.57%	98.41%	97.77%	96.65%	101.16%	98.61%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.03%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-3,457.36%	-407.65%	-274.53%	-337.36%	-198.51%	-32.10%	65.54%	-100.40%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-3,425.46%	-324.42%	-254.73%	-317.78%	169.42%	-39.00%	66.53%	-1,926.66%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	3,149.29%	136.30%	160.10%	221.69%	-9.78%	-92.05%	243.77%	30.85%
Return on Equity (ROE)	-225.07%	-45.76%	-91.44%	-308.07%	-271.35%	-114.43%	-115.67%	-208.29%	-124.16%	309.31%	-69.54%
Cash Return on Invested Capital (CROIC)	-3,497.90%	-1,479.61%	-2,627.87%	-2,838.92%	-877.95%	-645.30%	-719.77%	-473.32%	-181.10%	-122.88%	-93.93%
Operating Return on Assets (OROA)	-29.83%	-25.17%	-40.96%	-71.09%	-36.30%	-26.91%	-27.65%	-23.26%	-6.95%	12.89%	-13.48%
Return on Assets (ROA)	-24.52%	41.13%	-39.77%	-69.59%	-35.90%	-26.52%	-27.17%	-22.76%	-6.73%	13.03%	1.72%
Return on Common Equity (ROCE)	-225.07%	-45.76%	-91.44%	-308.07%	-271.35%	-114.43%	-115.67%	-208.29%	-124.16%	309.31%	-69.54%
Return on Equity Simple (ROE_SIMPLE)	-263.93%	-31.11%	0.00%	-217.53%	-963.28%	1,154.05%	0.00%	-690.70%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-73	-65	-66	-97	-47	-39	-43	-30	-8.86	25	-23
NOPAT Margin	-226.01%	-174.71%	-146.39%	-235.57%	-87.58%	-62.49%	-56.85%	-36.55%	-7.74%	15.12%	-17.50%
Net Nonoperating Expense Percent (NNEP)	-9.21%	112.93%	-19.81%	-31.90%	-83.23%	-19.79%	-19.58%	-367.93%	6.90%	-0.99%	1,826.26%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-11.41%	-	-	-	-9.71%	-7.25%	-2.15%	6.47%	-5.32%
Cost of Revenue to Revenue	4.51%	3.47%	10.13%	3.64%	3.81%	2.59%	3.41%	5.72%	1.33%	0.96%	1.97%
SG&A Expenses to Revenue	211.84%	182.78%	141.12%	155.23%	119.70%	104.33%	92.93%	89.12%	66.59%	52.44%	78.42%
R&D to Revenue	206.52%	163.34%	132.60%	277.05%	100.40%	82.16%	82.99%	57.37%	43.13%	31.48%	44.62%
Operating Expenses to Revenue	418.36%	346.11%	299.00%	432.90%	221.30%	186.68%	177.80%	146.49%	109.72%	83.92%	123.04%
Earnings before Interest and Taxes (EBIT)	-104	-92	-93	-139	-71	-56	-61	-42	-13	25	-21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-93	-81	-83	-129	-61	-44	-49	-29	0.84	41	-3.23
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	9.84	2.40	3.36	7.82	41.31	0.00	23.01	48.45	40.14	28.96	29.77
Price to Tangible Book Value (P/TBV)	0.00	3.88	7.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3,561.19
Price to Revenue (P/Rev)	16.40	8.50	4.65	3.72	3.52	5.26	5.83	5.81	3.94	4.89	6.97
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	122.82	18.80	43.31	48.14	10.00	16.57	20.31	18.30	14.77	16.77	32.84
Enterprise Value to Revenue (EV/Rev)	14.85	5.23	3.35	3.31	3.82	5.76	5.87	6.02	4.12	5.02	6.94
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	508.53
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	90.19
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	3.29	1.35	1.88	5.10	24.96	-12.43	6.42	11.56	11.60	4.23	2.71
Long-Term Debt to Equity	3.23	1.35	1.88	5.10	24.96	-10.18	5.25	9.46	9.50	4.23	2.71
Financial Leverage	-1.02	-1.00	-1.00	-0.92	-0.42	-0.63	-0.70	-0.06	2.36	3.66	-0.02
Leverage Ratio	5.55	4.10	6.00	5.59	9.78	5.36	5.32	11.34	23.10	24.19	6.90
Compound Leverage Factor	5.43	3.96	5.72	5.46	9.56	5.29	5.24	11.09	22.33	24.48	6.80
Debt to Total Capital	76.69%	57.39%	65.26%	83.60%	96.15%	108.75%	86.51%	92.04%	92.06%	80.89%	73.08%
Short-Term Debt to Total Capital	1.38%	0.00%	0.00%	0.00%	0.00%	19.71%	15.68%	16.68%	16.68%	0.00%	0.00%
Long-Term Debt to Total Capital	75.31%	57.39%	65.26%	83.60%	96.15%	89.04%	70.84%	75.36%	75.38%	80.89%	73.08%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	23.31%	42.61%	34.74%	16.40%	3.85%	-8.75%	13.49%	7.96%	7.94%	19.11%	26.92%
Debt to EBITDA	-1.05	-1.04	-1.07	-0.98	-1.07	-1.19	-1.32	-2.06	-3.11	-8.53	46.52
Net Debt to EBITDA	0.29	0.71	0.54	0.16	-0.15	-0.32	-0.03	-0.31	-0.49	-1.56	-1.65
Long-Term Debt to EBITDA	-1.03	-1.04	-1.07	-0.98	-1.07	-0.98	-1.08	-1.69	-2.55	-8.53	46.52
Debt to NOPAT	-1.41	-1.35	-1.39	-1.25	-1.37	-1.51	-1.67	-2.39	-3.15	-4.88	-7.09
Net Debt to NOPAT	0.40	0.92	0.70	0.21	-0.19	-0.40	-0.04	-0.36	-0.50	-0.89	0.25
Long-Term Debt to NOPAT	-1.38	-1.35	-1.39	-1.25	-1.37	-1.24	-1.37	-1.95	-2.58	-4.88	-7.09
Altman Z-Score	-0.86	-0.50	-0.85	-1.97	-2.25	-2.29	-1.40	-1.28	-1.34	0.40	2.02
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.99	4.92	3.47	2.78	3.04	1.71	2.08	2.05	2.00	2.75	2.74
Quick Ratio	3.77	4.66	3.31	2.68	2.89	1.59	1.98	1.95	1.89	2.50	2.52
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-96	-110	-89	-98	-107	-88	-99	-109	-34	-35	-59
Operating Cash Flow to CapEx	-2,309,900.00%	-591,340.00%	0.00%	0.00%	-49,076.83%	0.00%	0.00%	0.00%	0.00%	10,226.43%	0.00%
Free Cash Flow to Firm to Interest Expense	-33.66	-38.99	0.00	0.00	-38.31	-31.69	0.00	-38.21	-11.96	-12.66	-25.76
Operating Cash Flow to Interest Expense	-24.37	-20.96	0.00	0.00	-14.43	-15.31	0.00	-14.77	1.75	5.20	26.45
Operating Cash Flow Less CapEx to Interest Expense	-24.38	-20.97	0.00	0.00	-14.46	-15.31	0.00	-14.77	1.75	5.15	26.45
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.09	0.10	0.20	0.21	0.28	0.30	0.34	0.45	0.60	0.84	0.82
Accounts Receivable Turnover	3.77	5.79	7.68	7.04	7.92	10.24	9.66	9.58	10.57	8.06	9.15
Inventory Turnover	0.44	0.43	1.64	1.57	0.76	0.72	0.99	2.58	2.06	1.74	1.71
Fixed Asset Turnover	7.49	8.99	17.57	19.38	23.45	28.74	36.39	46.38	59.93	83.16	104.88
Accounts Payable Turnover	0.37	0.31	0.39	0.53	0.41	0.41	0.24	0.68	0.46	0.50	0.43
Days Sales Outstanding (DSO)	96.84	63.00	47.53	51.88	46.09	35.65	37.80	38.10	34.54	45.29	39.89
Days Inventory Outstanding (DIO)	826.60	853.37	222.08	232.95	479.43	507.54	367.88	141.47	177.00	210.15	213.14
Days Payable Outstanding (DPO)	994.64	1,177.94	939.84	693.04	886.69	896.71	1,536.76	536.50	790.86	731.20	853.17
Cash Conversion Cycle (CCC)	-71.19	-261.57	-670.23	-408.21	-361.17	-353.52	-1,131.08	-356.93	-579.32	-475.77	-600.14
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	8.45	22	11	11	68	71	67	90	93	130	104
Invested Capital Turnover	-23.22	-123.59	-382.71	14.68	4.65	4.39	5.93	5.43	4.15	4.34	5.74
Increase / (Decrease) in Invested Capital	23	45	23	0.22	59	49	56	79	25	60	36
Enterprise Value (EV)	1,038	413	486	516	679	1,171	1,368	1,647	1,375	2,187	3,408
Market Capitalization	1,146	671	676	579	626	1,070	1,360	1,590	1,314	2,130	3,419
Book Value per Share	$1.56	$3.73	$2.67	$0.96	$0.20	($0.40)	$0.76	$0.37	$0.37	$0.83	$1.28
Tangible Book Value per Share	($0.51)	$2.30	$1.28	($0.35)	($1.18)	($1.76)	($0.58)	($0.80)	($0.82)	($0.40)	$0.01
Total Capital	500	657	578	452	393	348	438	412	413	385	427
Total Debt	383	377	377	378	378	379	379	379	380	311	312
Total Long-Term Debt	376	377	377	378	378	310	310	311	311	311	312
Net Debt	-108	-258	-190	-63	53	101	8.29	57	60	57	-11
Capital Expenditures (CapEx)	0.00	0.01	0.00	0.00	0.08	0.00	0.00	0.00	0.00	0.14	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-78	-88	-128	-133	-78	-74	-86	-62	-61	-18	-45
Debt-free Net Working Capital (DFNWC)	413	547	439	308	248	203	285	260	259	236	278
Net Working Capital (NWC)	406	547	439	308	248	135	216	192	190	236	278
Net Nonoperating Expense (NNE)	13	-216	24	39	23	16	18	11	3.90	-0.78	-25
Net Nonoperating Obligations (NNO)	-108	-258	-190	-63	53	101	8.29	57	60	57	-11
Total Depreciation and Amortization (D&A)	11	11	9.49	9.88	10	11	12	13	14	16	18
Debt-free, Cash-free Net Working Capital to Revenue	-111.74%	-111.32%	-88.12%	-85.53%	-43.73%	-36.44%	-36.91%	-22.58%	-18.17%	-4.24%	-9.20%
Debt-free Net Working Capital to Revenue	591.28%	692.94%	302.17%	197.69%	139.44%	99.93%	122.07%	95.23%	77.54%	54.16%	56.58%
Net Working Capital to Revenue	581.41%	692.94%	302.17%	197.69%	139.44%	66.21%	92.61%	70.09%	56.92%	54.16%	56.58%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.13)	$1.97	($1.07)	($1.76)	($0.91)	($0.70)	($0.71)	($0.47)	($0.14)	$0.29	$0.03
Adjusted Weighted Average Basic Shares Outstanding	76.00M	76.31M	74.27M	77.14M	77.50M	77.78M	78.89M	88.36M	88.95M	89.23M	89.21M
Adjusted Diluted Earnings per Share	($1.13)	$1.97	($1.07)	($1.76)	($0.91)	($0.70)	($0.71)	($0.47)	($0.14)	$0.28	$0.04
Adjusted Weighted Average Diluted Shares Outstanding	76.00M	76.31M	74.27M	77.14M	77.50M	77.78M	78.89M	88.36M	88.95M	102.62M	89.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	75.01M	75.15M	76.10M	76.13M	76.49M	78.05M	88.74M	88.80M	89.14M	89.47M	92.24M
Normalized Net Operating Profit after Tax (NOPAT)	-73	-65	-58	-97	-47	-39	-42	-30	-8.86	25	-23
Normalized NOPAT Margin	-226.01%	-174.71%	-128.69%	-235.13%	-86.73%	-62.35%	-55.54%	-36.55%	-7.74%	15.12%	-17.50%
Pre Tax Income Margin	-316.40%	-240.54%	-196.47%	-328.15%	-128.55%	-87.18%	-80.68%	-50.39%	-11.13%	15.60%	-16.24%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-36.63	-32.70	0.00	0.00	-25.54	-20.03	0.00	-14.74	-4.63	9.24	-9.31
NOPAT to Interest Expense	-25.59	-22.97	0.00	0.00	-17.00	-14.15	0.00	-10.46	-3.11	9.06	-9.90
EBIT Less CapEx to Interest Expense	-36.64	-32.70	0.00	0.00	-25.57	-20.03	0.00	-14.74	-4.63	9.19	-9.31
NOPAT Less CapEx to Interest Expense	-25.60	-22.98	0.00	0.00	-17.03	-14.15	0.00	-10.46	-3.11	9.01	-9.90
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Travere Therapeutics, Inc. (TVTX) has shown a notable improvement in top-line growth and liquidity over the last several quarters, with continued investment in R&D and SG&A. The company carries a meaningful long-term debt load, but its cash position and some quarterly profitability trends have strengthened in 2024–2025. Below is a concise, investor-focused take based on the last four years of quarterly statements.

Strong revenue momentum into 2025: Quarterly operating revenue climbed from around mid-80s million in early 2025 to a peak of 164.9 million in Q3 2025, before easing to about 129.7 million in Q4 2025, signaling meaningful top-line growth over the period.
Robust gross profits support margin discipline: Total Gross Profit reached approximately 163.3 million in Q3 2025, with gross margin historically robust relative to revenue, and still substantial in Q4 2025 at about 127.1 million.
Profitability improvement in select quarters: Consolidated net income turned positive in Q3 2025 (about 25.7 million) and remained in positive territory in Q4 2025 (about 2.7 million attributable to common shareholders), indicating improving quarterly profitability on a trailing basis.
Liquid balance sheet position improving through 2024–2025: Cash & equivalents rose to roughly 110.9 million by Q3 2025 (vs. about 36.4 million in Q3 2024), strengthening liquidity and optionality for ongoing clinical development and potential strategic moves.

Discontinued operations add earnings volatility: Periods with discontinued operations materially impact net income (e.g., Q4 2025 shows discontinued income of about 24.7 million), making quarterly profitability less predictable.
Ongoing, sizable operating investments: High ongoing SG&A and R&D expenses (SG&A around 86–87 million and R&D around 50–60 million in 2025 quarters) reflect continued investment in development pipelines, contributing to near-term operating losses in several quarters.
Occasional equity funding activity: The company has engaged in issuing common equity in some periods, which can provide liquidity but may dilute existing shareholders over time; the effect appears episodic rather than a steady source of funding.

Persistent quarterly losses and negative operating cash flow in several quarters: Despite some positive quarters, multiple periods show net losses (e.g., Q2 2025 consolidated net income around -12.8 million; Q1 2025 around -41.3 million) and negative operating cash flow (e.g., Q1 2025 net cash from continuing operating activities around -119.0 million).
Significant long-term debt burden: Long-term debt hovers around 311 million in 2025, contributing to a sizeable liabilities load and interest expense that presses profitability and cash flow margins.
Ongoing cash burn risk despite liquidity gains: While cash on hand has risen, quarterly cash burn from operations has been meaningful in several periods, underscoring ongoing reliance on financing or asset sales to fund operations.

05/05/26 05:43 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Travere Therapeutics' Financials

When does Travere Therapeutics' fiscal year end?

According to the most recent income statement we have on file, Travere Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Travere Therapeutics' net income changed over the last 10 years?

Travere Therapeutics' net income appears to be on an upward trend, with a most recent value of -$25.55 million in 2025, falling from $117.24 million in 2015. The previous period was -$321.55 million in 2024. View Travere Therapeutics' forecast to see where analysts expect Travere Therapeutics to go next.

What is Travere Therapeutics' operating income?

Travere Therapeutics' total operating income in 2025 was -$62.82 million, based on the following breakdown:

Total Gross Profit: $480.39 million
Total Operating Expenses: $543.21 million

How has Travere Therapeutics' revenue changed over the last 10 years?

Over the last 10 years, Travere Therapeutics' total revenue changed from $99.89 million in 2015 to $490.73 million in 2025, a change of 391.3%.

How much debt does Travere Therapeutics have?

Travere Therapeutics' total liabilities were at $490.36 million at the end of 2025, a 8.4% decrease from 2024, and a 131.0% increase since 2015.

How much cash does Travere Therapeutics have?

In the past 10 years, Travere Therapeutics' cash and equivalents has ranged from $37.81 million in 2015 to $165.75 million in 2021, and is currently $93.04 million as of their latest financial filing in 2025.

How has Travere Therapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Travere Therapeutics' book value per share changed from 8.30 in 2015 to 1.28 in 2025, a change of -84.5%.

Related Companies

Financial statements for NASDAQ:TVTX last updated on 2/22/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Travere Therapeutics (TVTX) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Travere Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Travere Therapeutics (TVTX) Financials

Annual Income Statements for Travere Therapeutics

Quarterly Income Statements for Travere Therapeutics

Annual Cash Flow Statements for Travere Therapeutics

Quarterly Cash Flow Statements for Travere Therapeutics

Annual Balance Sheets for Travere Therapeutics

Quarterly Balance Sheets for Travere Therapeutics

Annual Metrics And Ratios for Travere Therapeutics

Quarterly Metrics And Ratios for Travere Therapeutics

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Travere Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools